Recombinant Human CD27 Ligand/TNFSF7 Protein, CF Summary
|GCN4-IZ||GGGSGGGSGGGS||Human CD27 Ligand
Accession # P32970
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 200 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Recombinant Human CD27 Ligand/TNFSF7 (Catalog # 9328-CL)induces IL-8 secretion in HT1080 human fibrosarcoma cells transfected withHuman CD27. The ED50 for this effect is 5-25 ng/mL.
Background: CD27 Ligand/TNFSF7
ligand (CD27L), also named CD70, is a type II transmembrane glycoprotein
belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7 (1, 2).
Human CD27L cDNA encodes a 193 amino acid (aa) residue protein with a 17 aa N-terminal cytoplasmic domain, a 21 aa transmembrane domain and a 155 aa
C-terminal extracellular domain. Human and mouse CD27L share approximated 56% aa sequence identity. CD27L is expected to exist as non-covalent homotrimers. CD70
is constitutively expressed on medullary thymic epithelial cells (mTECs) in
human and mouse and on certain unconventional APCs in the mouse intestine (3).
CD70 is also exclusively expressed on DCs (5), B cells (5), conventional- and
regulatory T cells (6) and NK cells (7) but only after their activation. CD70
expression is highly regulated by antigen through Pattern Recognition Receptors
(PRRs), T cell and B cell antigen receptors (8), and further tuned by cytokines
such as IL-1 alpha,
IL-12, TNF alpha, prostaglandin E2 and by CD28 and CD40 co-stimulation (9). Ligation of CD27 on T cells provides co-stimulatory signals and promotes T cell proliferation, antigen-specific CD4+ and CD8+ T cells clonal expansion, effector & memory T-cell differentiation, and effector T-cell survival & T-cell memory formation (10-12). Ligation of CD27 on mouse B cell and NK cells promotes the B- and NK-cell response by supporting B-cell expansion in the germinal center and increasing IFN-gamma levels in NK cells, in turn enhancing NK cytotoxic capability, which can contribute to tumor control (13,14). Overall, CD27/CD70 co-stimulatory system promote T, B and NK cell responses and particularly the CTL response, and is a target in cancer immunotherapy (15).
- Bowman MR. et al. J Immunol. (1994) 152:1756.
- Croft, M. (2003) Nature Reviews Immunol. 3:609.
- Tesselaar K. et al. (2003) J. Immunol. 170:33.
- Sanchez PJ. et al. (2007) J. Immunol. 178:1564.
- Lens SM. et al. (1998) Semin. Immunol. 10:491.
- Koenen HJ. et al. (2005) J. Immunol. 174:7573.
- Hintzen RQ. et al. (1994) Int. Immunol. 6:477.
- Borst J. et al. (2005) Curr. Opin. Immunol. 17:275.
- Krause P. et al. (2009) Blood 113:2451.
- Van Gisbergen K. et al. (2011) Immunity 35:97.
- Peperzak V. et al. (2010) J. Immunol. 185:6670.
- Pen JJ. et al. (2013) J. Immunol. 191:1976.
- Shin CA, et al. (2016) Oncotarget 7:46173.
- Takeda K. et al. (2000) J. Immunol. 164:1741.
- Wajant H. (2016) Expert Opin Ther Targets 20:959.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human CD27 Ligand/TNFSF7 Protein, CF
Average Rating: 5 (Based on 1 Review)
Have you used Recombinant Human CD27 Ligand/TNFSF7 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image